We demonstrate the synergistic antitumor effect of oridonin and the PI3K/mTOR inhibitor NVP-BEZ235 on the non-germinal center B cell-like subtype of diffuse large B cell lymphoma (non-GCB DLBCL) both in vitro and in vivo. The underlying mechanism may be multifunctional, involving apoptosis, AKT/mTOR and NF-kB inactivation, and ROS-mediated DNA damage response. Our findings pave the way for a new potential treatment option for non-GCB DLBCL with the combination of oridonin and NVP-BEZ235.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995739 | PMC |
| http://dx.doi.org/10.1186/s13045-016-0303-0 | DOI Listing |
Publication Analysis
Top Keywords
oridonin pi3k/mtor
8
pi3k/mtor inhibitor
8
non-germinal center
8
center cell-like
8
cell-like subtype
8
subtype diffuse
8
diffuse large
8
large cell
8
cell lymphoma
8
non-gcb dlbcl
8
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!